INTRODUCTION AND OBJECTIVES: CG0070 is a selective oncolytic adenovirus that exploits retinoblastoma (Rb) pathway defects. We have previously shown promising interim results for this agent. We present mature results from a phase II trial for CG0070 in patients with BCG-unresponsive NMIBC who refused cystectomy.
METHODS: Sixty-seven patients with residual BCGunresponsive high-grade Ta, T1, or CIS AE Ta/T1 were accrued in this phase II single arm multicenter trial (NCT02365818). Patients were unable to achieve disease free state at 6 months after adequate BCG (BCG-refractory) or developed recurrence after complete response (CR) to BCG (BCG-relapsed). CR was defined as no disease on cystoscopy, cytology, and/or random biopsies. The primary endpoint was 18-month CR. Ten patients were excluded from analysis due to withdrawn consent or subsequent therapy despite continued CR prior to 18 months.
RESULTS: On analysis of 57 patients, the overall 18-month CR rate was 23%. Among stage subsets, 18-month CR was 19% for CIScontaining tumors (n[43), 19% for pure CIS (n[27) , and 36% for pure Ta, T1 or Ta/T1 disease (n[14) . No patients with T1/CIS or T1/ Ta/CIS had 18-month CR (n[6). BCG-refractory patients had 35% (n[23) 18-month CR, BCG-relapsed 17% (n[29), unknown 0% (n[5). There was a subset of patients with durable CR (Figure 1 ). Eleven patients underwent cystectomy, of whom 6 patients had muscle invasive disease. All treatment related adverse events (AEs) were Grade 1-3; immunologic AEs included influenza type illness (7%), fatigue (4%), and chills (1%). Six deaths were secondary to progressive urothelial carcinoma, esophageal carcinoma, lung carcinoma, and cardiac disease.
CONCLUSIONS: This phase II study demonstrates that in a high-risk BCG-unresponsive NMIBC population, intravesical CG0070 yielded overall 44%, 30%, and 23% complete response rates at 6, 12, and 18 months, respectively. Rb and checkpoint biomarker analysis is pending to attempt prediction of which patients have durable response to this agent. Bladder EpiCheck (BE) is a methylation-based urine marker for bladder cancer monitoring that demonstrated outstanding results in non low-grade (LG) tumors in the first analysis of its European multicenter study: sensitivity 91.7% and NPV 99.3% over specificity of 88.0% in 440 patients (1). The study continued recruiting, and this is its 2nd analysis.
Source of Funding: Cold Genesys
METHODS: This was a multicenter, prospective, blinded, single arm, single visit, cohort study performed in 7 centers in Europe and Israel under IRB.
Inclusion criteria: Age 22y, urothelial carcinoma undergoing cystoscopic surveillance at 3 months intervals, all UC resected within 12mths, able to produce 10 mL of urine, able to consent.
Exclusion criteria: Planning to undergo radical cystectomy or chemotherapy-radiation for UC.
BE is a urine assay using 15 proprietary methylation biomarkers to assess the presence of bladder cancer.
RESULTS: The demographic data was representative of NMIBC patients (Table 1) . Out of 822 patients, 81 did not have BE results and additional 84 did not have a definitive reference standard diagnosis of positive/negative. The final cohort for analysis had 657 patients: 80 positive (36 LG, 40 HG, 4 no path) and 577 negative.
Study Endpoints are presented in Figure 1 alongside the results from the first analysis. The results were similar between the two analyses in all parameters.
Sensitivity by grade of BE, cytology and cystoscopy are presented in figure 2. BE outperformed cytology in all categories (all-grade, LG and non-LG tumors). Cystoscopy outperformed BE and cytology in all-grades and LG tumors detection.
CONCLUSIONS: Consistent outstanding results with NPV of 99% in a large cohort further substantiates the evidence of BE as a robust rule-out test for high-grade cancers. Such high NPV with high specificity allows to safely utilize BE in NMIBC monitoring, even as an alternative to the standard methods that demonstrated inferior (cytology) or similar (cystoscopy) performance in this cohort. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e617
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